Pien Tze Huang, officially known as Pien Tze Huang Pharmaceutical Co., Ltd., is a prominent player in the traditional Chinese medicine industry, headquartered in China (CN). Established in 1955, the company has made significant strides in the herbal medicine sector, particularly in the production of its flagship product, Pien Tze Huang, a renowned remedy for various ailments. With a strong operational presence across Asia and expanding into international markets, Pien Tze Huang is celebrated for its commitment to quality and innovation. The company’s core offerings include traditional herbal formulations that blend ancient wisdom with modern manufacturing techniques, setting them apart in a competitive landscape. Recognised for its excellence, Pien Tze Huang has garnered numerous accolades, solidifying its position as a leader in the herbal medicine market.
How does Pien Tze Huang's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Pien Tze Huang's score of 22 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pien Tze Huang, headquartered in China (CN), currently does not have publicly available carbon emissions data for the most recent year, nor does it report specific reduction targets or commitments. The absence of emissions data suggests that the company may not have established a formal framework for tracking its carbon footprint or may not disclose this information publicly. Additionally, there are no climate pledges or initiatives reported, indicating a potential gap in their climate strategy. The company does not inherit emissions data from any parent or related organizations, as it operates independently in this regard. In the context of the pharmaceutical industry, where sustainability and climate commitments are increasingly important, Pien Tze Huang may need to consider developing a comprehensive climate strategy to align with industry standards and expectations. This could include setting science-based targets for emissions reductions and participating in initiatives such as the Carbon Disclosure Project (CDP) to enhance transparency and accountability in their environmental impact.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Pien Tze Huang has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
